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Abstract
Introduction: Melanoma and Merkel cell carcinoma (MCC) are both aggressive skin malignancies associated with 
immunosuppression and possible UV exposure. Both tumors get similar surgical treatment; however, MCC is a relatively 
rare tumor in which less is known about prognosis and clinical behavior.
Methods: The California Cancer Registry (CCR), a population-based registry, was reviewed from the years 1988–2003. 
Merkel cell carcinoma and melanoma were compared with relation to gender, age, ethnicity, disease stage, site, and 
survival.
Results: A total of 113,187 cases of melanoma and 1,878 cases of MCC were identiﬁ  ed in the CCR. Though both cancers 
are more common in men than in women, MCC had a higher incidence in men than melanoma (63% vs 57% p   0.005). 
MCC occurs in the more elderly, with 73.6% of cases occurring in people over 70 years. In contrast, 69% of melanoma 
cases occurred in people younger than 70 years (p   0.005). MCC shows a predilection for the head and neck compared to 
melanoma (47% vs 25.8%) Additionally, melanoma occurs more frequently on the trunk than MCC (30% vs 8.7%). Finally, 
the 10-year cumulative survival is lower for MCC than for melanoma (17.7% vs 61.3%, p   0.005).
Conclusion: Many clinicians assume MCC and melanoma behave similarly. However, MCC occurs in an older population, 
more frequently on the head and neck, in a higher percentage of men. Additionally, MCC has a higher rate of regional 
metastasis and thus may have more of a beneﬁ  t from regional staging procedures. Overall, MCC has a worse prognosis.
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Introduction
Melanoma and Merkel cell carcinoma (MCC) are both aggressive skin malignancies associated with 
immunosuppression and UV exposure. Merkel cell carcinoma, unlike melanoma, is exceedingly rare 
and relatively little is known about its epidemiology and prognosis. Because there are some clear 
similarities between the diseases and most clinicians have more experience and familiarity with mela-
noma, MCC has been considered and managed like melanoma.
The Merkel cell was ﬁ  rst described in 1875 by Freidrich Merkel. Like the melanocyte, the precursor 
to melanoma, it is a cell of neuroendocrine origin (Poulson, 2004). It is thought to be derived from the 
neural crest and migrates to the basal layer of the epidermis where it becomes a slow-acting mechano-
receptor. While the ﬁ  rst cases of melanoma were described well over 300 years ago, the ﬁ  rst cases of 
MCC were not diagnosed until 1972, when they were called “trabecular carcinoma of the skin.” (Holly 
et al. 1995; Poulson, 2004). It was later noted, in 1978, that these were tumors of the Merkel cell. His-
tologically, the tumor is a small-blue cell tumor which can resemble small-cell lung cancer, Ewing’s 
sarcoma or neuroblastoma (Poulson, 2004). It remains a rare tumor, and based on the most recent epi-
demiologic data available, the incidence of MCC is only 0.44/100,000 people within the U.S., while 
the incidence of melanoma is over 20/100,000 (Hodgson, 2005).328
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The primary treatment for both tumors is surgical 
excision. At present in the literature, there is level one 
data on the treatment of melanoma because it is a 
common tumor and easy to study; however, there is 
a paucity of data available on even the natural history 
of MCC. This study compares these two skin based 
tumors that are treated in a similar surgical fashion 
but have very a different prognosis. It was designed 
to examine the behavior of MCC using a population-
based cohort in order to highlight some of its distinct 
characteristics as compared to melanoma.
Methods
Material from the California Cancer Registry 
(CCR), a total population-based database, was 
reviewed from the years 1988 to 2003. The CCR 
(originally the California Tumor Registry) was 
established in the late 1940’s as a 10% sample of 
the incident cancer cases in the state. In 1988, can-
cer became mandatory reportable disease within 
California, and continues to be to this the present. 
All cancers are reported except basal and squamous 
cell carcinoma of the skin and, since the mid-
1990’s, cervical carcinoma in-situ and “borderline” 
tumors of the ovary. The database includes informa-
tion about cancer type (histology), patient demo-
graphics, disease stage at diagnosis and survival.
All Merkel cell carcinoma and melanoma cases 
were analyzed with relation to patient gender, 
ethnicity and age at presentation. Additionally, 
tumor location and disease stage were examined. 
For both MCC and melanoma, tumor stage was 
reported in the CCR as localized, regional, or 
metastatic. A Berkson-Gage life table was used to 
calculate cumulative survival and relative cumula-
tive survival. Relative survival rates compare the 
mortality of a group of patients to a group of 
people from the general population unaffected by 
the disease process in-question (Arias, 2002; 
Cronin and Feuer, 2000). Nominal data were com-
pared using a chi-square.
The CCR does not contain complete informa-
tion regarding treatment modality for all years so 
treatment data was not included in our study. 
Median follow-up was 5 years.
Results
Patient and tumor characteristics
A total of 1,878 cases of MCC and 113,187 cases 
of melanoma were identiﬁ  ed. The median age of 
the MCC patients was 75.5 years (range 24–105 
years), with 73.6% of cases occurring in patients 
over 70 years old. The median age for the melanoma 
patients was 57 years with a range of 0–107 years 
(p   0.05); 69.0% of cases occurred in patients 
younger than 70 years old. There was a signiﬁ  cantly 
higher percentage of men with MCC than with 
melanoma (63% vs 57%, p   0.005). (See Table 1)
MCC and melanoma occur in different loca-
tions. MCC and melanoma present with an equal 
frequency on the extremities (34.7% vs 39.7%, 
NS). MCC shows a predilection for the head and 
Table 1. Demographics of MCC and melanoma patients: gender, age, site of initial lesion, disease stage at 
presentation.
  MCC (%) n = 1878  Melanoma (%) n = 113,187  p-value
Gender    
 Male  63.0  57.0  p    0.005
 Female  37.0  43.0  p    0.005
Age    
   70 years  26.4  69.0  p   0.05
   70 years  73.6  31  p   0.05
Site    
 Extremities  34.7  39.7  NS
 Head/Neck  Face  47.1  25.8  p    0.001
 Trunk  8.7  30.2  p    0.005
 Other  9.5  4.3  NS
Stage    
 Localized  55.8  75.5  p    0.05
 Regional  11.0  3.1  p    0.05
 Metastatic  7.2  2.1  p    0.05
 Unreported  26  19.2  p    0.05329
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neck (47.1%), with only 25.8% of melanoma cases 
presenting in these areas (p   0.005). Melanoma 
occurs more frequently on the trunk (30.2%) than 
does MCC (8.7%, p   0.005).
For both MCC and melanoma, tumor stage was 
“unreported” in some cases (26.0% and 19.2%, 
respectively). The majority of cases of both MCC 
and melanoma presented with a localized lesion. 
Melanoma, however, had a higher percentage of 
patients with localized disease than MCC (75.5% 
vs 55.8%, p   0.05). MCC presented at an 
advanced stage at a higher rate than melanoma. 
Regional disease, with lymph node involvement, 
was present in 11.0% of MCC cases and in only 
3.1% of melanoma cases (p   0.05). Metastases 
were noted in 7.2% of MCC cases, whereas only 
2.1% of melanoma cases were metastatic at the 
time of presentation (p   0.05).
Both MCC and melanoma were most common 
in Caucasians (89.1% and 86.7%, respectively), 
and occurred very rarely in African-Americans 
(0.96% and 0.35%, respectively) or Hispanics 
(4.8% and 4.7%, respectively). The rate of MCC 
and melanoma in Caucasians was signiﬁ  cantly 
higher than the percentage of Caucasians in the 
California population (51%, p   0.001) and lower 
than the percentage of African-Americans and 
Hispanics in the state (6.9% and 29.9%, p   0.001). 
(See Table 2)
Survival
Figure 1 illustrates the cumulative survival rates 
for MCC and melanoma. After one year, the sur-
vival rate is 92.9% for patients with melanoma and 
only 57.7% for those with MCC (p   0.05). After 
10 years, the cumulative survival from melanoma 
is 61.3% compared to only 17.7% from MCC 
(p   0.05). The relative cumulative survival from 
melanoma was 94.7% at one year and 83.7% after 
10 years. MCC patients had a relative cumulative 
survival of 60.6% after 1 year and 40.2% after 
10 years. (See Fig. 2)
Discussion
Our review of the literature review suggests that this 
is the largest series of Merkel cell carcinoma to date 
with an analysis of over 1,800 cases. Because of its 
rarity, most of the previously published reports are 
in the form of small series and case reports with 
limited conclusions about the natural history and 
long-term outcomes from MCC.
Merkel cell carcinoma has been perceived as 
a disease of older men (Brown et al. 1999; Brissett 
et al. 2002; Koljonen, 2006; Manor, Bellaiche and 
Bodner, 2006). Indeed, in this study, the majority 
of patients with both MCC and melanoma were 
male, however there was a signiﬁ  cantly higher 
percentage of men with MCC. Both melanoma 
and MCC patients presented in a large range of 
ages, although only melanoma was noted in chil-
dren and young adults. The majority of melanoma 
cases occurred in patients younger than 70 years 
old while most patients with MCC were older 
than 70.
Melanoma has long been associated with UV 
exposure and numerous studies have illustrated a 
link between sun exposure and disease incidence 
(Marmelzat, 1977; Holman and Armstrong, 1984; 
Auteier et al. 1994). The cause of MCC has not 
been elucidated, though UV exposure has been 
proposed as a causative factor. A study by Miller 
and Rabkin found a statistical signiﬁ  cance between 
solar UVB index (annual exposure to UVB radia-
tion) and MCC cases (Miller and Rabkin, 1999). 
As the CCR contains data only from California, 
where there is a relatively uniform UVB index 
throughout the state, it was not possible to draw a 
conclusion regarding solar index and MCC inci-
dence. However, given that MCC has a higher 
propensity for sun-exposed areas, such as the head 
and neck region, this data suggest a possible 
correlation between MCC and UV exposure. Addi-
tionally, the ethnic distribution of both melanoma 
and MCC seen in the CCR supports the association 
between UV exposure and these malignancies, as 
Table 2. Breakdown of ethnicity in entire California population, Merkel cell carcinoma patients and melanoma patients.
  California (%)  MCC (%)  Melanoma (%)
Ethnicity    
 Caucasian  51.3  89.1  86.7
 African-American  6.9  0.95  0.35
 Hispanic  29.9  4.8  4.7
 Asian/Paciﬁ  c Islander  10.6  0.6  0.65
 American  Indian/Other/Unknown  1.3  7.4  2.6330
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they occur less frequently in highly pigmented 
groups.
MCC tends to present at a more advanced stage 
than melanoma. This may be explained in several 
ways. There may be a difference in the rates of early 
detection. Melanoma usually presents as an 
abnormal appearing mole or an atypical nevus 
which is easily recognizable by clinicians. 
Education programs have been created and tested 
to provide community-based melanoma education 
Figure 2.
Figure 1.331
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(Robinson, 1990; Kamin, O’Neill, and Ahearn, 
1993). Educational programs have been created to 
ensure that physicians and nurses are optimally 
trained to identify lesions and to help educate their 
patients to do so as well (Gerbert et al. 2002; 
Berwick et al. 2000). Melanoma’s tendency to 
occur with greater frequencies in families has 
prompted providers to focus on education the entire 
family once one member is diagnosed with mela-
noma (Hay et al. 2005). Because of the rarity of the 
tumor, such programs have not been established for 
MCC, and the tumor is not as easily identiﬁ  able. The 
nodule usually presents as a small, red or violet 
nodule that may resemble other benign cutaneous 
lesions and can be overlooked until it gets to an 
advanced stage (Wong et al. 1998; Poulson, 2004).
Many studies point to Merkel cell carcinoma’s 
aggressive tumor biology and tendency for early 
metastases, which may also play a part in the higher 
proportion of advanced staged disease. In a study 
by Wong et al., 82% of MCC cases developed 
metastases at a mean of only 13.4 months after 
diagnosis of the primary lesion (Wong, 1998). Our 
study shows an 11.0% rate of regional disease at 
the time of diagnosis. Though this is signiﬁ  cantly 
higher than the rate seen in melanoma, it is lower 
than the rates reported in other studies. Several 
series about MCC showed lymph node involve-
ment in over 20% of patients (Akhtar, Oza, and 
Wright, 2000; Eng et al. 2004). Disease stage was 
not reported in 26% of MCC cases within the CCR 
which may explain the lower rate of regional and 
metastatic disease in the CCR. Additionally, some 
cases that had no clinical evidence of metastasis 
may not have had full work-up for the presence of 
regional or distant disease involvement and may 
have been reported as localized without full inves-
tigation of tumor stage. The largest single institu-
tional experience in treating MCC is from 
Memorial Sloan Kettering in which they treated 
250 patients over 30 years. In their series, 
70 patients with clinically negative regional beds 
underwent regional staging with either an elective 
lymph node dissection or sentinel lymph node 
biopsy. They found that 16 patients (23%) had 
positive nodes. Therefore, it is likely that many 
patients in the CCR may be understaged (Allen 
et al. 2005).
Because of the rarity of the tumor and the over-
all poor prognosis of MCC, there is little survival 
data beyond 3 years reported in the literature. In 
small, retrospective studies, the 2-year survival 
rate was between 30%–50% (Koljonen, 2006). In 
contrast, the CCR contains long-term survival data, 
and analysis of this data conﬁ  rm the low overall 
survival rate from MCC, with only a 17.7% cumu-
lative survival after 10 years. Most patients with 
MCC are elderly, and the low survival rate could 
be thought to be inﬂ  uenced by their increased age 
and consequent comorbities. The relative cumula-
tive survival rate, however, compares the mortality 
of these patients to people from the general popu-
lation with equivalent ages and comorbidities. The 
decreased relative survival rate, therefore, should 
only reﬂ  ect the impact of MCC. At 10 years, the 
cumulative survival for people with MCC is only 
40.2% of that of the general population.
Given the poor outcomes from MCC, there has 
been an effort to improve treatment options. MCC, 
like melanoma, is treated surgically with wide local 
excision. Unlike melanoma, however, there is 
limited data on whether sentinel lymph node biopsy 
is beneficial in MCC. Morton et al. recently 
showed, in a prospective randomized trial, that 
patients with intermediate thickness melanoma 
who underwent a lymph node staging and subse-
quent lymph node dissection had an improved 
survival compared to patients who were observed 
(Morton et al. 2006). Because of the rarity of the 
tumor, such a study has been difﬁ  cult to complete 
for MCC, but there is data to suggest that SLN 
biopsy may prove valuable for Merkel cell carci-
noma patients as well. In the Memorial series, 
pathologic staging of the draining nodal basin was 
associated with improved stage-speciﬁ  c survival 
and decreased nodal recurrence (Allen et al. 2005). 
Similarly, a recent study reviewed a single institu-
tion’s experience as well as small reports from the 
literature and showed that patients with MCC who 
had a positive sentinel lymph node biopsy and 
received adjuvant treatment had an improved sur-
vival compared to patients who did not receive 
adjuvant treatment (Morton et al. 2006). Further-
more, a study focused on Merkel cell carcinoma 
of the head and neck showed that all patients who 
underwent wide local incision of the primary tumor 
with dissection of the lymphatic drainage basin 
were alive at 2 years as opposed to 68% who had 
wide local excision alone (Brissett et al. 2002). 
Though the recent Memorial study did not show 
any beneﬁ  t to adjuvant treatment for patients with 
regional or widely metastatic disease, they did 
demonstrate that pathologic nodal status was 
the only independent predictor of survival 332
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(Allen et al. 2005). The data from the CCR in our 
study shows a lower rate of advanced tumors com-
pared to most studies, which suggests that lymph 
node and distant metastases may not be evident to 
all clinicians, and even if sentinel lymph node 
biopsy is not essential for therapy, it may be valu-
able for accurate staging and counseling patients 
about prognosis.
Because the CCR does not contain inclusive 
information regarding treatment for all years, we 
were unable to analyze outcomes as they relate to 
treatment. Several studies, however, have shown 
improved outcomes with adjuvant radiation espe-
cially in patients with regional metastasis. 
Additionally, as MCC appears histologically 
similar to small cell carcinoma of the lung, similar 
chemotherapy regimens have been used in con-
junction with radiation in high risk patients and 
have shown improved outcomes (Poulson et al. 
2003). Subsequent studies, however, have failed 
to show any survival beneﬁ  t with the use of adju-
vant chemotherapy and have not advocated its use. 
Given the overall low survival seen in our study, 
further studies developing optimal adjuvant treat-
ment protocols are warranted.
Conclusion
MCC is a very rare tumor and, with such a low 
incidence, most clinicians may see only a few cases 
in their career. Given the aggressive nature of the 
disease, however, knowledge of its unique charac-
teristics are valuable for patient care. Overall, MCC 
has fundamental differences from melanoma. It 
affects an older patient population, in a higher 
percentage of men and occurs more frequently on 
UV exposed areas, like the head and neck. MCC 
has a signiﬁ  cantly higher rate of regional metasta-
sis than melanoma, and lymph node status has 
important prognostic implications and may help 
guide management. Overall, the prognosis is worse 
for MCC than melanoma and more studies need to 
be focused on adjuvant treatments for this aggres-
sive disease.
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